RayKnowChina Research Map
Shortlist0

Other diseases

Moyamoya disease

烟雾病Moyamoya

A progressive narrowing and blockage of the main arteries inside the skull, with a network of small vessels forming at the base of the brain. It occurs in children and adults; studies in China find two age peaks, the larger one in adults.

Definition adapted from MeSH (US National Library of Medicine), World Neurosurg 2019, Stroke Vasc Neurol 2021

Not in the first or second national rare-disease catalogue (2018, 2023; checked 10 November 2026).

hospitals in mainland China
47

with a paper from 2016–2025 or a registered study

cities
26

where those hospitals are

open trials in China
15

ClinicalTrials.gov, 8 Nov 2026

Mainland China accounts for 29% of the world's English-language research papers on moyamoya disease, 2021–2025 (22% in 2016–2020), and 49% of the world's registered trials on it have a site in China.

Research activity in public records, not a rating of care and not medical advice. How the numbers are made

47 hospitals in 26 cities

Order: papers led on moyamoya disease, 2021–2025, then A–Z. Research activity, not a rating of care.

A hospital is listed when it led at least 2 papers or 1 trial on moyamoya disease, or was a site in 2 or more trials. “Papers led” counts English-language PubMed papers whose first or last author lists the hospital first. Hospitals not listed may also treat it. Definitions

A square is a city. Its size and number are hospitals listed for this disease, not the amount of research. Choose one to show that city in the hospital list and the trial list.

Cities with the most listed hospitals

  1. Beijing8
  2. Shanghai4
  3. Guangzhou3
  4. Nanjing3
  5. Wuhan3
  6. Changchun2
  7. Kunming2
  8. Nanchang2
  9. Tianjin2
  10. Zhengzhou2

Each opens moyamoya disease in that city. 16 more cities are in the menu below.

  1. Beijing Tiantan Hospital

    首都医科大学附属北京天坛医院BeijingInternational Department

    60 papers led
  2. Chinese PLA General Hospital

    中国人民解放军总医院Beijing

    46 papers led
  3. 17 papers led
    No open trial led
  4. 13 papers led
    No open trial led
  5. 12 papers led
    No open trial led
  6. 11 papers led
    No open trial led
  7. 10 papers led
    No open trial led
  8. 9 papers led
    No open trial led
  9. 7 papers led
    No open trial led
  10. Xuanwu Hospital

    首都医科大学宣武医院Beijing

    7 papers led
    No open trial led
  11. Nanfang Hospital

    南方医科大学南方医院Guangzhou

    6 papers led
    No open trial led
  12. 6 papers led
    No open trial led
  13. Xiangya Hospital

    中南大学湘雅医院Changsha

    6 papers led
    No open trial led
  14. 5 papers led
    No open trial led
  15. 5 papers led
    No open trial led
  16. First Affiliated Hospital of USTC

    中国科学技术大学附属第一医院(安徽省立医院)Hefei

    5 papers led
    No open trial led
  17. 5 papers led
    No open trial led
  18. 4 papers led
  19. 4 papers led
    No open trial led
  20. 4 papers led
    No open trial led
  21. 4 papers led
    No open trial led
  22. Fujian Medical University Union Hospital

    福建医科大学附属协和医院Fuzhou

    4 papers led
    No open trial led
  23. 4 papers led
    No open trial led
  24. First Affiliated Hospital of Shandong First Medical University

    山东第一医科大学第一附属医院(山东省千佛山医院)Jinan

    3 papers led
    No open trial led
  25. 3 papers led
    No open trial led
  26. Jiangsu Province Hospital

    江苏省人民医院(南医大一附院)Nanjing

    3 papers led
  27. 3 papers led
    No open trial led
  28. 3 papers led
    No open trial led
  29. Tongji Hospital

    华中科技大学同济医学院附属同济医院WuhanInternational Medical Department

    3 papers led
  30. 2 papers led
    No open trial led
  31. 2 papers led
    No open trial led
  32. 2 papers led
    No open trial led
  33. 2 papers led
    No open trial led
  34. 2 papers led
    No open trial led
  35. China-Japan Union Hospital, Jilin University

    吉林大学白求恩第三医院(中日联谊医院)Changchun

    2 papers led
    No open trial led
  36. 2 papers led
    No open trial led
  37. 2 papers led
    No open trial led
  38. Huadong Hospital, Fudan University

    复旦大学附属华东医院Shanghai

    2 papers led
    No open trial led
  39. 2 papers led
    No open trial led
  40. 2 papers led
    No open trial led
  41. Ruijin Hospital

    上海交通大学医学院附属瑞金医院Shanghai

    2 papers led
    No open trial led
  42. 2 papers led
    No open trial led
  43. Southwest Hospital, Army Medical University

    陆军军医大学第一附属医院(西南医院)Chongqing

    2 papers led
    No open trial led
  44. 2 papers led
    No open trial led
  45. Union Hospital

    华中科技大学同济医学院附属协和医院Wuhan

    2 papers led
    No open trial led
  46. 2 papers led
    No open trial led
  47. Xijing Hospital

    空军军医大学西京医院Xi'an

    2 papers led
    No open trial led

By university or health system 31

Hospitals carrying a university’s name, added together, plus papers that name only the university. Same order as above.

  1. Capital Medical University

    首都医科大学Beijing

    71 papers led
    6 hospitals
  2. Chinese PLA General Hospital

    中国人民解放军总医院Beijing

    46 papers led
    1 hospital
  3. Fudan University

    复旦大学Shanghai

    24 papers led
    4 hospitals
  4. Zhengzhou University

    郑州大学Zhengzhou

    17 papers led
    3 hospitals
  5. Wuhan University

    武汉大学Wuhan

    13 papers led
    1 hospital
  6. Zhejiang University School of Medicine

    浙江大学医学院Hangzhou

    12 papers led
    1 hospital
  7. Sichuan University (West China)

    四川大学华西Chengdu

    11 papers led
    2 hospitals
  8. Peking Union Medical College / Chinese Academy of Medical Sciences

    北京协和医学院/中国医学科学院Beijing

    10 papers led
    1 hospital
  9. Nanchang University

    南昌大学Nanchang

    9 papers led
    3 hospitals
  10. Peking University Health Science Center

    北京大学医学部Beijing

    9 papers led
    3 hospitals
  11. Nanjing Medical University

    南京医科大学Nanjing

    7 papers led
    4 hospitals
  12. Nanjing University

    南京大学Nanjing

    7 papers led
    1 hospital
  13. Southern Medical University

    南方医科大学Guangzhou

    7 papers led
    2 hospitals
  14. Sun Yat-sen University

    中山大学Guangzhou

    7 papers led
    2 hospitals
  15. Central South University (Xiangya)

    中南大学湘雅Changsha

    6 papers led
    1 hospital
  16. Jilin University

    吉林大学Changchun

    6 papers led
    2 hospitals
  17. Huazhong Univ. of Sci. & Tech. – Tongji Medical College

    华中科技大学同济医学院Wuhan

    5 papers led
    2 hospitals
  18. Shandong First Medical University

    山东第一医科大学Jinan

    5 papers led
    3 hospitals
  19. 5 papers led
    1 hospital
  20. Fujian Medical University

    福建医科大学Fuzhou

    4 papers led
    1 hospital
  21. Guangxi Medical University

    广西医科大学Nanning

    4 papers led
    2 hospitals
  22. Shanghai Jiao Tong University School of Medicine

    上海交通大学医学院Shanghai

    4 papers led
    3 hospitals
  23. Soochow University

    苏州大学Suzhou

    4 papers led
    2 hospitals
  24. Hebei Medical University

    河北医科大学Shijiazhuang

    3 papers led
    2 hospitals
  25. Shandong University

    山东大学Jinan

    3 papers led
    3 hospitals
  26. Tianjin Medical University

    天津医科大学Tianjin

    3 papers led
    3 hospitals
  27. Air Force Medical University

    空军军医大学Xi'an

    2 papers led
    1 hospital
  28. Army Medical University

    陆军军医大学Chongqing

    2 papers led
    1 hospital
  29. Harbin Medical University

    哈尔滨医科大学Harbin

    2 papers led
    2 hospitals
  30. Kunming Medical University

    昆明医科大学Kunming

    2 papers led
    1 hospital
  31. Qingdao University

    青岛大学Qingdao

    2 papers led
    1 hospital

15

open trials on moyamoya disease in China

Recruiting, not yet recruiting, or by invitation, as registered on ClinicalTrials.gov on 8 Nov 2026, with at least one listed hospital as lead sponsor or site. 15 of them are led by a listed hospital. Check the registry for the current status. Whether someone can take part is decided by the study team.

Trials registered only in China’s own registry (ChiCTR) are not included. Questions to check before asking about a trial

What the phases mean (US National Cancer Institute)

  1. Recruiting
    5T MRI and Metabolomics-Based Hemorrhage Risk Prediction in Moyamoya Disease
    Phase
    Not given
    Started
    2026-02
    Registry
    NCT07781579

    Age not stated (registered criteria)

    Led by Beijing HospitalBeijing

  2. Recruiting
    Efficacy and Safety of Ischemic Preconditioning Therapy Versus Optimal Medical Therapy in Reducing the Recurrence of Ischemic Events in Symptomatic Moyamoya Disease
    Phase
    N/A
    Started
    2026-10
    Registry
    NCT07889531

    Age 18 years to 70 years (registered criteria)

    Led by Beijing Tiantan HospitalBeijing

  3. Recruiting
    Development and Validation of Risk Prediction Models for Stroke and Cognitive Impairment in Moyamoya Disease and Moyamoya Syndrome
    Phase
    Not given
    Started
    2026-08
    Registry
    NCT07894107

    Age 12 years to 70 years (registered criteria)

    Led by Beijing Tiantan Hospital; 12 listed hospitals as study sitesBeijing, Chengdu, Hangzhou, Nanchang, Shanghai, Suzhou, Wuhan, Zhengzhou

  4. Recruiting
    Treatment of Moyamoya Disease With iPSC-derived Exosomes
    Phase
    Phase 1
    Started
    2025-05
    Registry
    NCT07065409

    Age 18 years to 75 years (registered criteria)

    Led by Tongji HospitalWuhan

  5. Recruiting
    Study on Evaluating the Effectiveness of Statins in the Treatment of Moyamoya Disease
    Phase
    Not given
    Started
    2024-12
    Registry
    NCT06817434

    Age 18 years to 60 years (registered criteria)

    Led by Beijing Tiantan HospitalBeijing

  6. Recruiting
    Study on the Mechanism of Cognitive Impairment in Patients with Moyamoya Disease
    Phase
    Not given
    Started
    2024-12
    Registry
    NCT06832839

    Age 18 years to 60 years (registered criteria)

    Led by Beijing Tiantan HospitalBeijing

  7. Recruiting
    Family-Based Moyamoya Susceptibility and Early Detection
    Phase
    Not given
    Started
    2024-11
    Registry
    NCT07517354

    Age not stated (registered criteria)

    Led by Beijing Tiantan Hospital; 1 listed hospital as study siteBeijing

  8. Recruiting
    Functional Magnetic Resonance-Based Observations of Brain Networks in Moyamoya Disease Patients Under Anesthesia
    Phase
    Not given
    Started
    2023-10
    Registry
    NCT06041659

    Age 18 years to 65 years (registered criteria)

    Led by Beijing Tiantan HospitalBeijing

  9. Recruiting
    Long-term Outcomes of Conservative Management in Patients with Moyamoya Disease and Their First-degree Relatives (LAMORA)
    Phase
    Not given
    Started
    2022-05
    Registry
    NCT05332756

    Age 2 years to 60 years (registered criteria)

    Led by Beijing Tiantan HospitalBeijing

  10. Recruiting
    The Evolution and Prognosis of Moyamoya Disease
    Phase
    Not given
    Started
    2022-09
    Registry
    NCT05619068

    Age 10 years to 60 years (registered criteria)

    Led by Chinese PLA General HospitalBeijing

  11. Recruiting
    Registry of Multicenter Brain-Heart Comorbidity in China
    Phase
    Not given
    Started
    2012-01
    Registry
    NCT05961748

    Age 18 years to Not stated (registered criteria)

    Led by Beijing Tiantan Hospital; 4 listed hospitals as study sitesBeijing, Harbin, Shanghai, Zhengzhou

  12. Not yet recruiting
    Evaluating Antiplatelet and Physical Therapy for Slowing Progression in Mild Moyamoya Disease.
    Phase
    N/A
    Started
    2026-07
    Registry
    NCT07762547

    Age 18 years to 70 years (registered criteria)

    Led by Beijing Tiantan HospitalBeijing

  13. Enrolling by invitation
    Fufang Tongluo Decoction as an Adjunct to Aspirin and Atorvastatin for Ischemic Moyamoya Disease
    Phase
    N/A
    Started
    2024-12
    Registry
    NCT07875335

    Age 18 years to 60 years (registered criteria)

    Led by Jiangsu Province HospitalNanjing

  14. Enrolling by invitation
    Clinical Safety and Efficacy Evaluation of the Blood-cooling and Stasis-removing Formula as an Adjunct to Atorvastatin in the Treatment of Hemorrhagic Moyamoya Disease.
    Phase
    Early phase 1
    Started
    2024-12
    Registry
    NCT07894640

    Age 18 years to 60 years (registered criteria)

    Led by Jiangsu Province HospitalNanjing

  15. Enrolling by invitation
    Clinical Evaluation of the Safety and Efficacy of "Buyan Huan Wu Tang" Combined With Atorvastatin in the Treatment of Atypical Pneumonia
    Phase
    Early phase 1
    Started
    2024-12
    Registry
    NCT07906652

    Age 18 years to 60 years (registered criteria)

    Led by Jiangsu Province HospitalNanjing

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

Before contacting a hospital

The same for every disease, so it is kept on one page. Each hospital page also has an enquiry letter in English and Chinese, and a name card to show staff.

Where these numbers come from

Papers

356 English-language PubMed papers on moyamoya disease with an author in mainland China, 2021–2025; a hospital led a paper when its first or last author lists it first. Run the PubMed search

Trials

ClinicalTrials.gov records with a listed hospital as lead sponsor or site, as of 8 Nov 2026. ChiCTR is not included. Search ClinicalTrials.gov

Locations

Locations are shown at city centres. Check the hospital’s website for its address.

Suggest a correctionDownload the data (CSV)Definitions